AMR Roundtable Part 1: Incentives Spur Antimicrobial Investments, But More Needed
Scrip spoke with the CEOs of antibiotic firm Zavante and antifungal specialist Amplyx as well as a BARDA official who oversees antibiotic funding programs during a roundtable discussion at BIO about what's needed to boost antimicrobial drug development. Topics addressed in this part 1 of the discussion include company funding strategies, impact of the CARB-X program, and unique opportunities and challenges for antifungals.
You may also be interested in...
Podcast with CARB-X Executive Director Kevin Outterson and BARDA Acting Deputy Director Joe Larsen describes the work of the accelerator, which just announced the first eleven projects in its portfolio.
The biotech startups that will be supported by a new transatlantic public-private partnership could end up with innovative products enticing enough to get some large biopharmaceutical firms back into the antibiotic game.
Bad news might be good news in the long term if Astellas’ woes highlight need for special antimicrobial reimbursement, which is one provision of the 21st Century Cures Act.